Sign In
Buy AYTU
$2.23
+0.0800 (+3.72%)
At Close: Jul 31, 2026
Aytu BioPharma, Inc. (AYTU) Q2 2025 Earnings Call Transcript
06:27pm, Wednesday, 12'th Feb 2025
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q2 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Josh Disbrow - Chief Executive
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
04:03pm, Wednesday, 12'th Feb 2025
Net income of $0.8 million Adjusted EBITDA1 of $1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025
05:50pm, Wednesday, 05'th Feb 2025
DENVER, CO / ACCESS Newswire / February 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
09:00am, Monday, 06'th Jan 2025
DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that C
Aytu BioPharma Disclosure Notification
11:45pm, Tuesday, 03'rd Dec 2024
DENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT O
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)
09:00am, Friday, 22'nd Nov 2024
DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it r
Aytu BioPharma, Inc. (AYTU) Q1 2025 Earnings Call Transcript
07:25pm, Wednesday, 13'th Nov 2024
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2025 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki
Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
04:05pm, Wednesday, 13'th Nov 2024
Net income of $1.5 million Adjusted EBITDA1 of $1.9 million ADHD Portfolio net revenue up 1% to $15.3 million Pediatric Portfolio net revenue up 54% sequentially $20.1 million cash balance at Septembe
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024
05:20pm, Wednesday, 06'th Nov 2024
DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its opera
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
04:15pm, Monday, 14'th Oct 2024
DENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh
Once approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release tablets for the treatment of ADHD commercialized in Canada DENVER, CO / ACCESSWIRE / Octob
Aytu BioPharma, Inc. (AYTU) Q4 2024 Earnings Call Transcript
06:51pm, Thursday, 26'th Sep 2024
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2024 Results Conference Call September 26, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
04:15pm, Thursday, 26'th Sep 2024
Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 million Full year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023 Full year fisca
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
05:30pm, Thursday, 19'th Sep 2024
DENVER, CO / ACCESSWIRE / September 19, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its ope
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
05:20pm, Thursday, 08'th Aug 2024
DENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that J
